Projects per year
Abstract
Hearing loss has become the most common sensory disorder worldwide. Despite intensive research on the pathophysiology of hearing loss, biological therapeutic approaches are limited by the anatomical and physiological characteristics of the inner ear. Challenges in inner ear drug delivery involve biotherapeutic instability, membrane inaccessibility and delivery non-specificity. With the development of nanotechnology, the nanoparticle-based delivery systems are promising to overcome these limitations. After drugs loading and stabilization, nanoparticles can carry the drugs into the inner ear by crossing round window membrane. The surface bioconjugation of ligand endows nanoparticles with specific targeting capability. Nanoparticles with stimuli-responsive moieties can provide a controlled release manner. Together, these strategies show great potential for hearing loss treatment. Understanding the current advances of nanotechnology in hearing loss treatment will facilitate future therapeutic options and clinical applications.
Original language | English |
---|---|
Pages (from-to) | 350-353 |
Journal | Smart Materials in Medicine |
Volume | 2 |
DOIs | |
Publication status | Published - Nov 2021 |
MoE publication type | A1 Journal article-refereed |
Fingerprint
Dive into the research topics of 'Nanoparticle-based inner ear delivery systems for the treatment of hearing loss'. Together they form a unique fingerprint.Equipment
-
Åbo Akademi Functional Printing Center
Toivakka, M. (PI), Rosenholm, J. (PI), Anttu, N. (PI), Bobacka, J. (PI), Huynh, T. P. (PI), Peltonen, J. (PI), Wang, X. (PI), Wilen, C.-E. (PI), Xu, C. (PI), Zhang, H. (PI) & Österbacka, R. (PI)
Faculty of Science and EngineeringFacility/equipment: Facility
-
FCFH: Finland-China Network in Food and Health Sciences
Rosenholm, J. (Principal Investigator), Xu, C. (Principal Investigator) & Zhang, H. (Principal Investigator)
Ministry of Education and Culture
01/01/21 → 31/12/24
Project: Ministry / Government Agency
-
Targeted delivery of CRISPR/Cas9 for advanced liver cancer therapy through c-Myc knockout
Zhang, H. (Principal Investigator)
01/09/19 → 31/08/24
Project: Research Council of Finland/Other Research Councils